Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints president of global pharmaceuticals

Luke Miels joins from AstraZeneca

GlaxoSmithKline Luke MielsGlaxoSmithKline has appointed Luke Miels as president of global pharmaceuticals, succeeding Abbas Hussain.

Miels joins the UK-headquartered firm from AstraZeneca, where he is currently executive vice president of AZ's European business. Prior to this, Miels served as executive vice president of global product and portfolio strategy, global medical affairs and corporate affairs.

He moved to AZ from Roche in 2014, having been regional vice president of its Asia-Pacific pharmaceutical operations, based in Shanghai, Singapore, after promotion from vice president and head of metabolism and anemia global marketing for Roche Switzerland.

He also brings management experience from Sanofi's operations in the US, Thailand, New Zealand and Australia to the role.

Emma Walmsley, GSK's chief executive officer designate, said: “Luke brings a combination of excellent R&D insight and a strong track record of commercial execution.

“We are now entering a critical period of commercialisation for our new pharmaceutical products and, over the next two to three years, we have important data to come on our early-stage pipeline.

“Luke will bring a strong new voice to the decisions and choices we will have to make for our pharmaceuticals business. I am delighted he has agreed to join GSK and look forward to welcoming him to the executive team.”

26th January 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....